Conference Coverage

Tildrakizumab shows positive effects in active psoriatic arthritis

Publish date: July 8, 2019

 

REPORTING FROM EULAR 2019 CONGRESS

SOURCE: Mease PJ et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):77-9. Abstract LB0002, doi: 10.1136/annrheumdis-2019-eular.8669

Pages

Recommended Reading

Carotid ultrasound may aid cardiovascular risk stratification of patients with psoriatic disease
Psoriatic Arthritis Resource Center
Ixekizumab surpasses adalimumab in PsA head-to-head study
Psoriatic Arthritis Resource Center
VIDEO: Dr. Lihi Eder on the diagnostic challenges of psoriatic arthritis
Psoriatic Arthritis Resource Center
Obesity might be targetable driver of psoriatic arthritis progression
Psoriatic Arthritis Resource Center
Infections linked with transition to psoriatic arthritis
Psoriatic Arthritis Resource Center
Psoriatic Arthritis Journal Scan: June 2019
Psoriatic Arthritis Resource Center
PsA Fast Facts: PsA and psoriasis links
Psoriatic Arthritis Resource Center
EULAR keeps csDMARDs as top PsA drugs
Psoriatic Arthritis Resource Center
Unacceptable pain despite inflammation control commonly occurs in PsA patients
Psoriatic Arthritis Resource Center
Dr. Alexis Ogdie discusses the latest research in psoriatic arthritis
Psoriatic Arthritis Resource Center